Tags : Hyrimoz

Sandoz’s Hyrimoz (adalimumab) Receives EU Approval for Autoimmune Disorders

Shots: The approval is based on non-inferiority data assessing Hyrimoz vs reference biologic in patients with rheumatoid arthritis, plaque psoriasis, Crohn’s disease, uveitis and ulcerative colitis The study demonstrated in meeting al 1EPs and resulted bioequivalence in terms of safety, efficacy, PK, immunogenicity in patients with moderate to severe chronic plaque-type psoriasis Hyrimoz (adalimumab) is […]Read More